+65 3158 9940
1300 798 820
+64 9801 0299
Singapore, 22 September 2021: SINGAPORE patients with an aggressive form of lung cancer (metastatic small cell cung cancer) can now access a new therapy that may improve outcomes. The drug ZEPZELCA (lurbinectedin) has been provisionally approved by Singapore’s Health Sciences Authority (HSA) “for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who
Singapore, 14 September 2021: AUSTRALIAN patients with an aggressive form of lung cancer (metastatic Small Cell Lung Cancer) can now access a new therapy that may improve outcomes. The therapy, ZEPZELCA™ (lurbinectedin) has been approved by the Therapeutic Goods Administration (TGA) “for the treatment of patients with metastatic small cell lung cancer (SCLC) that has progressed
Singapore, 9 September 2021: A globally regarded sarcoma therapy that has been shown to improve progression free survival1 is now being re-introduced in key regions of South-East Asia by independent pharmaceutical company Specialised Therapeutics Asia (STA). The compound YONDELIS® (trabectedin) will be available to advanced sarcoma patients via their treating oncologists in Singapore, Malaysia and
Melbourne, Australia, 15 March 2021: BREAST cancer patients who wish to have a genomic test that may help them to avoid chemotherapy can now take out interest-free payment plans of up to two years to pay for the test, following an exclusive arrangement between independent pharmaceutical company Specialised Therapeutics Australia (STA) and Latitude Finance.
Singapore, 06 November 2020: A NEW therapy to treat advanced gastrointestinal stromal tumours (GIST) will be available to patients in Australia, New Zealand and in some parts of South East Asia, following an exclusive distribution agreement. Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed an agreement with US-based Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) to commercialise the
Melbourne, Australia, 8 October 2020: Independent pharmaceutical company Specialised Therapeutics Australia (STA) has been recognised as an Employer of Choice in The Australian Business Awards 2020. The prestigious awards recognize organisations demonstrating business innovation, product innovation, technological achievement and employee engagement via a set of comprehensive award categories. The Employer of Choice (EOC) accolade in particular,
Singapore, 23 July 2020: Independent pharmaceutical company Specialised Therapeutics Asia (ST Asia) has appointed two senior executives to its Singapore team, as it drives commercialisation of new oncology products in the region. Dr Bhuvana Ramaswamy will commence as Senior Medical Advisor for South East Asia in October, bringing extensive oncology, scientific and pharmaceutical industry expertise to the
Singapore, 17 July 2020: A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is now approved for use in Malaysia. The drug, NERLYNX (neratinib), is an oral medication taken by women with breast cancer who have had surgery, chemotherapy and prior trastuzumab-based therapy. It has been shown to significantly reduce
Singapore and Melbourne, Australia, 3 June 2020: A NOVEL marine-derived drug to treat Small Cell Lung Cancer (SCLC) has been granted a provisional designation by the Therapeutic Goods Administration (TGA), based on encouraging results from an international trial evaluating its safety and efficacy in several solid tumours, including SCLC. Data from a key Phase 2
Singapore, 23 April 2020: A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is now commercially available to Singapore patients. The drug, NERLYNX (neratinib), is an oral medication taken by women with breast cancer who have had surgery, chemotherapy and prior trastuzumab-based therapy. It has been shown to significantly reduce